Home Cart Sign in  
Chemical Structure| 59880-97-6 Chemical Structure| 59880-97-6

Structure of For-Met-Leu-Phe-OH
CAS No.: 59880-97-6

Chemical Structure| 59880-97-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

N-Formyl-Met-Leu-Phe is a chemotactic peptide that can inhibit the secretion of TNF-alpha, holding potential for research into immune responses and inflammatory processes.

Synonyms: N-Formyl-Met-Leu-Phe; fMLP; N-Formyl-Met-Leu-Phe, FMLP

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of For-Met-Leu-Phe-OH

CAS No. :59880-97-6
Formula : C21H31N3O5S
M.W : 437.55
SMILES Code : O=C(N[C@@H](CC(C)C)C(N[C@@H](CC1=CC=CC=C1)C(O)=O)=O)[C@H](CCSC)NC=O
Synonyms :
N-Formyl-Met-Leu-Phe; fMLP; N-Formyl-Met-Leu-Phe, FMLP
MDL No. :MFCD00036780
InChI Key :PRQROPMIIGLWRP-BZSNNMDCSA-N
Pubchem ID :443295

Safety of For-Met-Leu-Phe-OH

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Guinea-pigs Normal guinea-pigs Intravenous injection 0.3, 1, 3, 10, 30 μg/kg 45-minute intervals To investigate the effects of FMLP on bronchoconstriction and leukopenia in guinea-pigs. FMLP induced dose-dependent bronchoconstriction and leukopenia, accompanied by mild thrombocytopenia. Bronchoconstriction and leukopenia were not affected by prostacyclin, platelet depletion, the platelet-activating factor (Paf-acether) antagonist BN52021, or the histamine H1-antagonist mepyramine. Br J Pharmacol. 1986 Oct;89(2):349-59
Mice PAR-1−/− and wild-type (WT) mice Intratracheal instillation 200 μg/50 μL Single dose, observed at 1, 3, 7, 14, and 21 days To investigate the role of PAR-1 in fMLP-induced inflammation and lung damage. Results showed that WT mice developed emphysema and goblet cell metaplasia after fMLP treatment, while PAR-1?/? mice exhibited inflammation and emphysema but were protected from goblet cell metaplasia. Am J Respir Cell Mol Biol. 2009 Dec;41(6):680-7

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.85mL

4.57mL

2.29mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories